

Freedom of Information Request: Our Reference CTMUHB_405_23

You asked:

I am analysing the usage of intra-vitreous injections or implants by the NHS. Could you please tell me how many of the following intra-vitreous injections/implants has your Health Board administered in the four-month period from May to August 2023:

- Aflibercept
- Bevacizumab - Avastin
- Bevacizumab - Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab - Ongavia

Our response:

Please find below the totals for the Health Board from May to August 2023:

• Aflibercept	2173
• Bevacizumab – Avastin	18
• Bevacizumab – Biosimilar	0
• Brolucizumab	0
• Dexamethasone	56
• Faricimab	620
• Fluocinolone acetonide	0
• Ranibizumab - Lucentis (pre-filled syringes)	14
• Ranibizumab - Lucentis (vials)	0
• Ranibizumab – Ongavia	0